Twist's AI-driven DNA demand and raised guidance fuel strong gains
AI genomic database deals drive new business Tech firms building genomic databases for AI models are outsourcing lab work to Twist, creating a new revenue stream. This growing demand for synthetic DNA pushes TWST's price up because it opens a large, fast-growing market beyond traditional biotech customers.
This is a new growth driver that directly boosts revenue expectations and investor enthusiasm.
Strong results and reaffirmed breakeven guidance Twist reported results well ahead of expectations and reaffirmed it will reach adjusted EBITDA breakeven in fiscal Q4 2026. This pushes the stock up because it shows the company is moving toward profitability while still growing quickly.
This is a new financial milestone that reassures investors about the company's path to profitability.
Raised fiscal 2026 revenue guidance to $456–$457 million Twist raised its full-year revenue outlook after a 23% jump in quarterly revenue, with DNA Synthesis and Protein Solutions up 39%. This lifts the stock because it signals stronger-than-expected demand and management confidence in future growth.
This is a new, concrete upward revision that directly affects valuation and investor confidence.
Biotech sector rally and Anthropic selection Biotech stocks hit post-pandemic highs after a major mRNA cancer trial win, and Anthropic chose Twist as an independent evaluator. This boosts TWST because sector-wide enthusiasm and a high-profile AI partnership increase demand for its services.
This is a new sector catalyst and partnership that raises Twist's visibility and demand outlook.